Skip to main content
Premium Trial:

Request an Annual Quote

NanoString Partners With CROs to Expand Access to Cancer Research Panel

NEW YORK (GenomeWeb) – NanoString said after the close of the market Thursday that it has signed commercial partnerships with three contract research organizations to expand commercial access to its PanCancer IO 360 Gene Expression Panel.

The deals with Covance, NeoGenomics Laboratories, and Navigate BioPharma Services will have two main areas of focus. First, NanoString will enable the CROs to offer and deliver a standardized research report that currently captures 47 gene expression signatures measuring the activity and abundance of immune and tumor cells.

In addition, NanoString has provided each CRO the rights to independently develop, validate, and offer, through their CLIA-licensed labs, translational research assays based on the 18-gene Tumor Inflammation Signature described in 2017 in The Journal of Clinical Investigation.

The IO 360 Panel, for research use only, runs on the company's nCounter Analysis System and provides a multifaceted characterization of disease biology and interrogation of multiple mechanisms of immune evasion.

"Biopharma companies have expressed a high level of interest in our 360 Series of gene expression panels and their proprietary analysis packages," Chad Brown, senior vice president of sales and marketing at NanoString, said in a statement. "We are excited to accelerate insights among biopharma researchers by enabling innovative CRO partners to provide these analyses and algorithms as part of their service offering."